CA-JUNIPER-NETWORKS
12.12.2022 15:35:36 CET | Business Wire | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that it has been selected by Deutsche Telekom (DT) as the first network technology partner for Magenta Business Networks SD-X. By leveraging the Juniper AI-driven Enterprise solution, DT’s innovative new universal managed services platform will power exceptional user experiences with simplified zero touch deployments, proactive self-driving automation, connected security and unique client-to-cloud insight.
SD-X is a cloud-based, virtualized and automated platform that will provide a rapid, simplified and cost-effective transition from MPLS to software-defined network services for thousands of European enterprises, including small-to-midsize organizations that might otherwise find the cost and complexity of owned infrastructure to be prohibitive. Juniper is providing DT with advanced technologies to create a secure, software-driven network fabric that uses AI to provide actionable insights on real-time performance coupled with automated mitigation. This approach enables SD-X to deliver optimal user, device and application experiences to its customers as they navigate digital transformation in support of agile, differentiated business capabilities. The managed services offered provide secure networking for campus and branch environments, enabling rich new service functionality and enhanced performance.
News Highlights
- Magenta Business Networks SD-X will leverage Juniper’s full AI-driven Enterprise portfolio, starting with secure SD-WAN and expanding to wired and wireless access.
- The Juniper solution provides client-to-cloud service levels with AI-driven intelligence to optimize and maintain the best user experiences. With AI-driven insight, problems are proactively discovered and addressed via recommended actions and/or self-driving network operations. This minimizes downtime while maximizing end user experiences on the SD-X network.
- Zero touch provisioning with automated workflows enable the SD-X solution services to be pre-configured and easily deployed remotely, saving time and money while minimizing installation errors. The time for new network services to be up-and-running is reduced from weeks or months to just a few days.
- Customers can easily change network policies and security settings remotely at any time using a cloud-hosted SD-X portal, with no manual intervention or site visits needed. Simultaneous updates can be made across a customer’s entire network, so consistent policies are applied between sites.
- By leveraging a microservices cloud, DT can easily update services across the entire Juniper portfolio with little to no downtime.
AI-driven Automation, Insight and Assurance Powers User Experience
The network is the digital lifeblood of today’s enterprise, requiring anywhere, anytime access between users and data. But increased levels of traffic, diversity in devices and distributed location of users can make it extremely challenging to deliver great experiences from client-to cloud. By deploying “smart” AI-driven networking technology from Juniper that can understand user behavior in real-time and automatically optimize the network to lower costs and maximize experiences, SD-X is able to deliver a differentiated and compelling managed service to its subscribers.
Supporting Quotes
“With the relentless pace and demands of modern businesses, our customers need managed services that optimize user experiences while minimizing operational costs. We have built SD-X as a gateway to accessible, progressive enterprise networking without the need for advanced in-house capabilities and technical resources. DT’s vision is made possible thanks to Juniper’s innovation with AI, automation and the cloud, which creates an agile network for our customers that is highly differentiated in the industry.”
- Sherif Rezkalla, VP Portfolio, Head of Business Networks, Deutsche Telekom
“DT has fully embraced the powerful value of intelligent networks with SD-X. This highly-scalable business model is more cost-effective than traditional approaches, while providing the agility and ease of use customers demand. In turn, these customers can use SD-X as the foundation for an experience-driven digital business for their own customers and employees. We look forward to working with DT to roll out more managed services across SD-X to deliver a game-changing networking experience.”
- Manoj Leelanivas, Chief Operating Officer, Juniper Networks
Additional Resources
Case Study: Deutsche Telekom transforms network service delivery
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
